Skip to main content
. 2005 Feb 19;334(1):74–82. doi: 10.1016/j.virol.2005.01.034

Fig. 3.

Fig. 3

Neutralizing activity of the RBD-specific antibodies isolated from the sera of SARS patients. (A) SARS-A; (B) SARS-B; (C) SARS-C; and (D) SARS-D. Inhibition of SARS pseudovirus infectivity in 293T/ACE2 cells by patient sera, flowthroughs, and eluates, respectively, at a series of 2-fold dilutions was determined and the percentage of neutralization was calculated for each sample.